Discounted Cash Flow Rating

Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

PolyMet Mining Corp. (PLM)

https://www.polymetmining.com

PolyMet Mining Corp is engaged in the exploration and development of natural resource properties. The company's primary mineral property is the NorthMet Project, which is a polymetallic project in northeastern Minnesota, USA. The NorthMet Project comprises two key elements: the NorthMet deposit (or Mine Site) and the Erie Plant. The company ultimately plans to produce metals such as copper, nickel, cobalt, gold, silver, and platinum.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/26/2006

Market Cap

408,366,000

Shares Outstanding

194,460,000

Weighted SO

194,460,251

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

NEXA --.--%

SKE --.--%

FURY --.--%

IPX --.--%

CMP --.--%

GLG --.--%

EMX --.--%

MTRN --.--%

Beta

0.8050

Last Div

0.0000

Range

0.751-3.11

Chg

-0.0100

Avg Vol

149409

Mkt Cap

408366000

Exch

AMEX

Country

US

Phone

651 389 4100

DCF Diff

0.4193

DCF

3.0193

Div Yield

0.0000

P/S

0.0000

EV Multiple

-24.3830

P/FV

0.7820

Div Yield %

0.0000

P/E

-17.9032

PEG

0.2479

Payout

0.0000

Current Ratio

20.0952

Quick Ratio

2.9818

Cash Ratio

2.9141

DSO

0.0000

DIO

129462.1273

Op Cycle

0.0000

DPO

5.8745

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.2421

ROA

-0.0407

ROE

-0.0574

ROCE

-0.0230

NI/EBT

1.3050

EBT/EBIT

1.3658

EBIT/Rev

0.0000

Debt Ratio

0.0003

D/E

0.0003

LT Debt/Cap

0.0001

Total Debt/Cap

0.0003

Int Coverage

-1.8453

CF/Debt

-125.7163

Equity Multi

1.0740

Rec Turnover

0.0000

Pay Turnover

62.1333

Inv Turnover

0.0028

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.0936

FCF/Share

-0.1239

Cash/Share

0.0744

OCF/Sales

0.0000

FCF/OCF

1.3236

CF Coverage

-125.7163

ST Coverage

-264.5672

CapEx Coverage

-3.0898

Div&CapEx Cov

-3.0898

P/BV

0.7820

P/B

0.7820

P/S

0.0000

P/E

-17.9032

P/FCF

-17.4047

P/OCF

-22.4320

P/CF

-22.4320

PEG

0.2479

P/S

0.0000

EV Multiple

-24.3830

P/FV

0.7820

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 02:23 Tactical Resources Corp. Announces Closing of Debenture Offering Benzinga Jan 02, 21:10 Palomar Holdings, Inc. Completes Acquisition of First Indemnity of America Insurance Company GlobeNewswire Inc. Jan 19, 16:15 Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency GlobeNewswire Inc. Jan 17, 16:30 Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference GlobeNewswire Inc. Jan 02, 16:30 Apollomics to Present at the 2024 Biotech Showcase GlobeNewswire Inc. Nov 29, 07:30 Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference GlobeNewswire Inc. Nov 28, 04:45 Veea to Become Publicly Traded Company via proposed Business Combination with Plum Acquisition Corp. I Benzinga Nov 27, 13:41 Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session GlobeNewswire Inc. Nov 12, 20:07 Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination GlobeNewswire Inc. Nov 12, 20:07 Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination GlobeNewswire Inc. Nov 12, 20:07 Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination GlobeNewswire Inc. Nov 12, 20:07 Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination GlobeNewswire Inc. Oct 31, 08:30 Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation GlobeNewswire Inc. Oct 26, 08:50 Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Revenue Product Segmentation